Investigation of Autophagy Markers in Endometrial Polyps
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- autophagy marker
Study Overview
Brief Summary
The aim of this research is to evaluate autophagy markers in patients with endometrial polyps
Detailed Description
Endometrial polyp are benign formations that are frequently encountered in gynecology practice and have malignant potential. It may be asymptomatic in the clinic or may present with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed, there are many studies in the literature about it. However, the autophagy pathway emerges as a subject that has never been evaluated. In this study, the investigators would like to prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in endometrial polyp tissue samples by immunohistochemistry and reveal their importance.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 35 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp
- •patients over the age of 35 whose histopathologically reported normal endometrial biopsy results.
Exclusion Criteria
- •Are under the age of 35,
- •those with cognitive dysfunction,
- •diagnosed with any type of cancer
- •who are under treatment for cancer,
- •diabetes mellitus,
- •hypertension,
- •endometriosis,
- •adenomyosis,
- •chronic endometritis,
- •have an acute or chronic illness,
- •patients who have smoked and used alcohol in the last 10 years
Outcomes
Primary Outcomes
autophagy marker
Time Frame: through study completion, an average of 1 year
p62 gene level
Secondary Outcomes
No secondary outcomes reported
Investigators
Burak Sezgin
Principal investigator M.D. Burak Sezgin
Muğla Sıtkı Koçman University